[go: up one dir, main page]

MX2010003989A - Composicion zibotentan que contiene mannitol y/o celulosa microcristalina. - Google Patents

Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.

Info

Publication number
MX2010003989A
MX2010003989A MX2010003989A MX2010003989A MX2010003989A MX 2010003989 A MX2010003989 A MX 2010003989A MX 2010003989 A MX2010003989 A MX 2010003989A MX 2010003989 A MX2010003989 A MX 2010003989A MX 2010003989 A MX2010003989 A MX 2010003989A
Authority
MX
Mexico
Prior art keywords
composition
sulphonamidewithma
nnitol
methylpyrazin
oxadiazol
Prior art date
Application number
MX2010003989A
Other languages
English (en)
Inventor
John David Blyth
Andrew John Day
Kieran James Lennon
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40534840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003989(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010003989A publication Critical patent/MX2010003989A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describe una composici?n farmac?utica que comprende N-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil )piridin-3-sulfonamida (es decir zibotentan o ZD4054) con manitol y/o celulosa microcristalina.
MX2010003989A 2007-10-12 2008-10-09 Composicion zibotentan que contiene mannitol y/o celulosa microcristalina. MX2010003989A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97973607P 2007-10-12 2007-10-12
US8911808P 2008-08-15 2008-08-15
PCT/GB2008/050928 WO2009047565A2 (en) 2007-10-12 2008-10-09 Composition 064

Publications (1)

Publication Number Publication Date
MX2010003989A true MX2010003989A (es) 2010-04-27

Family

ID=40534840

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003989A MX2010003989A (es) 2007-10-12 2008-10-09 Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.

Country Status (34)

Country Link
US (2) US8168221B2 (es)
EP (2) EP2209501B1 (es)
JP (1) JP2011500548A (es)
KR (1) KR20100099113A (es)
CN (1) CN101896210A (es)
AR (1) AR068845A1 (es)
AT (1) ATE536893T1 (es)
AU (1) AU2008309385B2 (es)
BR (1) BRPI0818323A2 (es)
CA (1) CA2701385A1 (es)
CL (1) CL2008003022A1 (es)
CO (1) CO6270344A2 (es)
CR (1) CR11363A (es)
CU (1) CU20100064A7 (es)
CY (1) CY1112433T1 (es)
DK (1) DK2209501T3 (es)
DO (1) DOP2010000105A (es)
EA (1) EA201000545A1 (es)
ES (1) ES2377426T3 (es)
HR (1) HRP20120085T1 (es)
IL (1) IL204953A0 (es)
MX (1) MX2010003989A (es)
NI (1) NI201000052A (es)
NZ (1) NZ585310A (es)
PE (1) PE20091032A1 (es)
PL (1) PL2209501T3 (es)
PT (1) PT2209501E (es)
SG (1) SG182138A1 (es)
SI (1) SI2209501T1 (es)
SV (1) SV2010003529A (es)
TW (1) TW200924768A (es)
UY (1) UY31385A1 (es)
WO (1) WO2009047565A2 (es)
ZA (1) ZA201002477B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102718708A (zh) 2003-06-06 2012-10-10 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
EP2209501B1 (en) 2007-10-12 2011-12-14 AstraZeneca AB Zibotentan composition containing mannitol and microcrystalline cellulose
CN101822796B (zh) * 2010-03-17 2012-01-04 山西仟源制药有限公司 一种银冰含片及制备方法和应用
EP2568973A2 (en) * 2010-05-11 2013-03-20 Sensient Colors LLC Film coating composition and methods of making and using the same
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
BR112014026439B1 (pt) * 2012-04-27 2022-05-31 Merck Patent Gmbh Formulação farmacêutica sob a forma de um comprimido revestido, e seu processo de preparação
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
KR20220164068A (ko) 2012-07-16 2022-12-12 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
LT3003284T (lt) * 2013-06-06 2020-04-27 Fibrogen, Inc. Hif hidroksilazės inhibitoriaus farmacinės kompozicijos
AU2021250160A1 (en) * 2020-03-31 2022-10-06 Eisai R&D Management Co., Ltd. Tablet, medicine, and method and kit for manufacturing said tablet and medicine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674794A (en) * 1970-03-18 1972-07-04 Ciba Geigy Corp Certain-3-pyridine-sulfonamide derivatives
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US6432994B1 (en) * 1997-04-28 2002-08-13 Texas Biotechnology Corporation Sulfonamides for treatment of endothelin-mediated disorders
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
JP2001058944A (ja) * 1999-06-18 2001-03-06 Takeda Chem Ind Ltd 速崩壊性固形製剤
EP1203580A4 (en) * 1999-06-18 2004-06-30 Takeda Chemical Industries Ltd QUICKLY DISINTERABLE SOLID PREPARATIONS
EP1446118B1 (en) * 2001-11-13 2008-01-09 Pharmacia Corporation Oral dosage form of parecoxib
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US20060030581A1 (en) * 2002-09-20 2006-02-09 Debusi Laura A Mannitol formulation for integrin receptor antagonist
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US7772232B2 (en) 2004-04-15 2010-08-10 Bristol-Myers Squibb Company Quinazolinyl compounds as inhibitors of potassium channel function
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
CN101032464A (zh) * 2007-04-01 2007-09-12 杨喜鸿 含有利莫那班和聚乙烯吡咯烷酮的组合物、固体分散体及其制备和药物应用
EP2209501B1 (en) 2007-10-12 2011-12-14 AstraZeneca AB Zibotentan composition containing mannitol and microcrystalline cellulose

Also Published As

Publication number Publication date
US20090099203A1 (en) 2009-04-16
PT2209501E (pt) 2012-02-03
ATE536893T1 (de) 2011-12-15
DK2209501T3 (da) 2012-02-27
SG182138A1 (en) 2012-07-30
EP2209501B1 (en) 2011-12-14
CO6270344A2 (es) 2011-04-20
HK1143095A1 (en) 2010-12-24
KR20100099113A (ko) 2010-09-10
ES2377426T3 (es) 2012-03-27
PE20091032A1 (es) 2009-08-15
NZ585310A (en) 2012-02-24
WO2009047565A3 (en) 2009-11-26
CL2008003022A1 (es) 2010-07-23
CA2701385A1 (en) 2009-04-16
DOP2010000105A (es) 2010-08-15
NI201000052A (es) 2011-03-24
UY31385A1 (es) 2009-05-29
HRP20120085T1 (hr) 2012-02-29
CN101896210A (zh) 2010-11-24
US20120177705A1 (en) 2012-07-12
TW200924768A (en) 2009-06-16
CU20100064A7 (es) 2011-10-05
JP2011500548A (ja) 2011-01-06
IL204953A0 (en) 2010-11-30
US8168221B2 (en) 2012-05-01
EA201000545A1 (ru) 2010-10-29
WO2009047565A2 (en) 2009-04-16
ZA201002477B (en) 2010-12-29
SI2209501T1 (sl) 2012-03-30
BRPI0818323A2 (pt) 2017-05-16
PL2209501T3 (pl) 2012-03-30
AU2008309385B2 (en) 2011-10-20
EP2433620A1 (en) 2012-03-28
CR11363A (es) 2010-07-14
SV2010003529A (es) 2010-09-13
AR068845A1 (es) 2009-12-09
AU2008309385A1 (en) 2009-04-16
EP2209501A2 (en) 2010-07-28
CY1112433T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
MX2010003989A (es) Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
MX2009003038A (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales.
MY152595A (en) 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate
MY150647A (en) 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
EA201001334A1 (ru) Твёрдый препарат гидрохлорида карипразина для перорального введения
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
TW200722421A (en) Azole derivatives as inhibitors of lipases and phospholipases
ATE506340T1 (de) 12-aryl-prostaglandin-analoga
TW200800954A (en) Novel crystal modifications
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
IS7766A (is) N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíð sem krabbameinslyf
CY1110942T1 (el) Αλας αιθανολαμινης n-(3-μεθοξυ-αιθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολο -2-υλ]φαινυλ)πυριδινο-3-σουλφοναμιδιου
EA200901387A1 (ru) Фармацевтическая композиция, включающая дезлоратадин
AU2008306604A8 (en) Process for the preparation of zolmitriptan, salts and solvates thereof
MX2008010233A (es) Composicion de liberacion modificada, que comprende doxofilina.
DK1848731T3 (da) Antibiotika 107891, dets faktorer, farmaceutisk acceptable salte og sammensætninger og anvendelse heraf
UA98676C2 (ru) Композиция зиботентана, содержащая маннит и микрокристаллическую целлюлозу
AR067351A1 (es) Combinacion de picotamida con nafronil
UA92592C2 (en) Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent such as taxane for the treatment of cancer
WO2009068906A3 (en) Combinations comprising zd4054 and a src family kinase inhibitor 172
WO2008024765A3 (en) Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds
NO20064510L (no) Oral mosidomin sammensetning med vedvarende frigjoring
WO2009024820A3 (en) Therapeutic treatment 014
EE200800014A (et) Ravimikoostis, mis on valmistatud p””rdtranskriptaasi inhibiitori ja meldooniumi baasil

Legal Events

Date Code Title Description
FG Grant or registration